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Abstract
Background: With the exponential expansion of clinical trials conducted in (Brazil, Russia, India, and China) and VISTA
(Vietnam, Indonesia, South Africa, Turkey, and Argentina) countries, corresponding gains in cost and enrolment efficiency
quickly outpace the consonant metrics in traditional countries in North America and European Union. However, questions
still remain regarding the quality of data being collected in these countries. We used ethnographic, mapping and computer
simulation studies to identify/address areas of threat to near miss events for data quality in two cancer trial sites in Brazil.
Methodology/Principal Findings: Two sites in Sao Paolo and Rio Janeiro were evaluated using ethnographic observations
of workflow during subject enrolment and data collection. Emerging themes related to threats to near miss events for data
quality were derived from observations. They were then transformed into workflows using UML-AD and modeled using
System Dynamics. 139 tasks were observed and mapped through the ethnographic study. The UML-AD detected four major
activities in the workflow evaluation of potential research subjects prior to signature of informed consent, visit to obtain
subjects informed consent, regular data collection sessions following study protocol and closure of study protocol for a
given project. Field observations pointed to three major emerging themes: (a) lack of standardized process for data
registration at source document, (b) multiplicity of data repositories and (c) scarcity of decision support systems at the point
of research intervention. Simulation with policy model demonstrates a reduction of the rework problem.
Conclusions/Significance: Patterns of threats to data quality at the two sites were similar to the threats reported in the
literature for American sites. The clinical trial site managers need to reorganize staff workflow by using information
technology more efficiently, establish new standard procedures and manage professionals to reduce near miss events and
save time/cost. Clinical trial sponsors should improve relevant support systems.
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Introduction
While clinical trials have typically been conducted in
developed countries such as the United States of America,
developing countries have recently emerged as important new
locations for clinical research [1]. In particular, the BRIC
countries (Brazil, Russia, India and China) and VISTA
(Vietnam, Indonesia, South Africa, Turkey, and Argentina),
with their large and ethnically diverse populations, have become
major players in the globalization of clinical research [2]. At the
same time, pharmaceutical companies are differentiating clinical
research capabilities across these countries to inform their
investment decisions. Among the most important capabilities is
the ability to deliver high quality data. As a result, efforts to
improve and ensure the production of high quality data in all
countries are essential for enhancing their competitiveness as
viable locations for the conduct of clinical trials, especially in
light of previous studies that have linked research in developing
countries with lower levels of data quality [3].
Even usual errors in data acquisition and transcription during
clinical trials can directly affect data quality, due to the additional
effort necessary to correct possible errors and ensure an acceptable
level of data quality. The typical example is that of a busy clinical
research coordinator (CRC) who is not adequately trained to
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39671collect data and who passes the task of data entry to another CRC
who might enter data that he/she does not understand.
While previous studies involving clinicians, radiology interpre-
tation, healthcare management systems, have evaluated the
relationship between workflow and data quality [4,5,6,7], most
have been conducted in a clinical rather than a research
environment, frequently using workflow data that had been
automatically captured. Although this approach is appealing, it
does not apply to a clinical research setting where each step of a
Principle Investigator (PI), Clinical research coordinator (CRC),
nurse, receptionist and pharmacist is not automatically captured in
an electronic system. Moreover, previous studies [5,8,9,10,11,12]
investigated methods of standardizing and improving the quality of
clinical trial procedures. Between them, only a few workflow
studies were conducted in research settings using a pure
ethnographic approach [13].
Recent studies have used Unified Modeling Language (UML)
[14] - a method that helps assess workplace efficiency, to assess and
suggest improvements in clinical research workflow [15,16,17].
UML is composed of a set of graphical notations initially created
to help understand software processes. It allows us to model a
system and help visualize and understand its operation. It is
currently used to model processes in diverse areas such as web
applications, business processes and health care [14].
Despite their benefits, UML models are static and hence are
limited by their description of a problem in a specific instance
in time. Dynamic models can be simulated to understand their
behaviour and analyze a range of ‘‘what if scenarios’’ thus
providing crucial information before the practical implementa-
tion of a system level change/policy. Previous studies have
[15,18,19,20] used simulation techniques to represent diverse
aspects of the real world in an interactive way. Systems
Dynamics (SD) a modeling and simulation technique has been
widely used to evaluate the behaviour of systems [21,22,23]. It
includes a set of principles for modeling and simulation that are
used to conceptualize and evaluate complex systems. Through a
SD model, we can represent the relationship between elements,
their activities as well as the flow and accumulation of
information between them. We can also feed the model with
qualitative and quantitative data and then create multiple
models representing a variety of ‘‘what if’’ scenarios that help in
decision making. Given the complex nature of health systems
and clinical research, SD has previously been used to model
decision support systems in this area [24,25,26,27].
Although there is a wide variety of publications in each of these
areas, to the best of our knowledge, no previous study has
evaluated the workflow [28] of clinical trials in depth through a
mix of techniques such as ethnographic studies to capture
information about work routine, used UML [14] to graphically
represent workflow in the form of activity diagrams [29] and SD
modeling [4,13,30] to evaluate the resulting behaviour over time.
Modeling and simulation performed before initiation of a clinical
trial may help trial planners and managers to improve the quality
of data and save time.
Accordingly, the objective of this study was to 1. Map the
workflow of PIs, CRC’s, nurses, receptionists and pharmacists of
two oncology clinical sites in Brazil, documenting ethnographic
observations using a standard task diagram language [14] and 2.
Introduce workflow modeling using UML and propose the use of
simulation modeling to understand the underlying behaviour of
the workflow model and 3. Conducting computer simulation
experiments [31] using a system dynamics approach [21] to
estimate work efficiency gains when solutions are applied.
Methods
Ethics
We obtained ethics approval from Comite ˆd eE ´tica em Pesquisa
do Hospital Pro Cardı ´aco, at Rua Dona Mariana, Rio de Janeiro,
Brazil and Comite ˆd eE ´tica em Pesquisa (CEPesq) of Hospital Sı ´rio
Libane ˆs,Sa ˜o Paulo, Brazil for conducting the study at the trial sites
in Rio de Janeiro and Sa ˜o Paulo respectively.
Inclusion and Exclusion Criteria
We evaluated two oncology trial sites working with Qualidoc
(consultant and training support at all levels of personnel in
ISO9001: 2008) recommended by Age ˆncia Nacional de Vigila ˆncia
Sanita ´ria (ANVISA) - a National Agency of Sanitary Surveillance
in Brazil. Both sites were located in Brazil: the first being a clinic-
based environment in the city of Rio de Janeiro with one PI
oncologist, two nurses CRCs, one pharmacist, one clinical
research administrator and fourteen studies in phase III and the
second being a hospital-based environment in Sa ˜o Paulo, with two
PIs oncologists, two nurses CRCs, four pharmacists, one clinical
research administrator and three studies in phase III. Both sites
present a high volume of trial recruitment. We considered sites
with an active phase III or IV trials as high volume sites. We
excluded Phase I and II trials since they do not represent the
majority of trials conducted in BRIC countries, also presenting a
very diverse workflow when compared to phase III/IV trials.
Operational Definitions
Although some technical terminology might encounter different
definitions across clinical trials, workflow, and qualitative research
literature, for the purposes of this manuscript, we have standard-
ized the most common concepts to facilitate understanding
(Table 1).
Ethnographic Study
Two researchers from our team [AB, EC] made ethnographic
field observations for approximately 40 hours and conducted
qualitative interviews at two sites in Rio de Janeiro and Sa ˜o Paulo
(Brazil), where they shadowed PIs, CRCs, nurses, receptionists and
pharmacists. We recorded information on tasks (S1), interactions
between other actors (defined in table 1), communication patterns,
information needs, and other aspects related to their workflow. We
conducted semi-structured interviews using open-ended questions
to complement and fill gaps in our ethnographic observations,
being broadly directed to (1) understand the average order of tasks
in different stages of each protocol, (2) main causes that affect the
average order of tasks, including the most common interruptions;
(3) main communication contacts for each actor, how frequently
communication occurs, how frequently the workflow is affected by
the patterns of communication and what type of noise affects the
performance of communication flow; (4) documentation models
and migration from paper to computer interface used for
documentation; (5) How documentation templates are affected
when trial site staff are confronted with any query about events, for
example, a subject enrolled sometime ago; (6) information
necessary that affect the workflow, causing the CRC to search
out information from different sources and need to contact other
personnel; (7) How clinical trial workflow has been integrated with
information technology and if there are in any area where some
disconnection between them exists causing a disruption in the
regular workflow. These seven concepts were extracted from the
study of Khan et. al. in [13].
Observations were made in a non-participatory manner, in that
observers were not directly involved in actively collecting data for
Workflow in Clinical Trial Sites and Data Quality
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effect that is characteristic of every observational study [32].
Observers did not have access to protected health information
(PHI) or any specific data related to the ongoing clinical trials to
ensure confidentiality. Since observers did not have access to raw
data for privacy and security reasons, the identification of data
quality issues was made following the concept of near miss events
(the happening of an unexpected event that did not generate
important problems, but had big potential to) [33]. Following is an
example of a near miss event: a CRC schedules an appointment in
his/her personal electronic calendar, notifying other staff person-
nel about the same. On the day of appointment, in the event of the
CRC’s absence, the patient would still be received and assisted by
other staff personnel at the site. Yet some important detail/
document, available only to the CRC may be missed during this
process. Consequently, it may generate a greater problem at the
end of the study.
When we observed a task that had a higher potential of near
miss events, we highlighted it as a potential problem. Information
on tasks was later submitted back to the staff at each of the two
sites to ensure that information was not misrepresented, thus
ensuring appropriate data triangulation [34].
All data collected through the ethnographic study and
interviews were transcribed in a Google Docs Word file. After
analysis, we synthesized emerging themes using atlas.ti [35], a
software for qualitative data analysis. Each interview was coded by
two researchers using Grounded Theory methods [36] where
emerging themes were extracted from patterns evolving from the
text and by avoiding pre-conceived hypothesis. Ambiguities if any
were resolved by discussion. Categories were reduced to major
themes through discussion amongst the study team while re-
reading the transcripts.
Observation Categories
Observers documented CRC tasks by selecting tasks descrip-
tions from a list of tasks compiled from the emerging themes
obtained from the previously described ethnographic study and by
findings from previous studies [13]. A large group of major and
minor categories were then used to facilitate the classification of
any possible CRC tasks. For the purpose of analysis, this large
group of tasks was summarized into a smaller number of
categories.
Workflow Mapping
Information from the ethnographic study was condensed using a
modified version of UML (Unified Modeling Language) Activity
Diagrams (UML-AD), version 2.0 [37]. All modeling was
conducted using Astah community version 6.1 [38]. The variation
of activities between two sites was represented by the workflow (S6)
pattern ‘‘exclusive choice’’ [39]. Exclusive choice represents a
situation where there are two or more exclusive alternate paths to
a workflow and only one of them can be chosen. The terminology
for workflow and UML- AD diagram are present in Supporting
information S6.
Preliminary Simulation Model
Next, we formed an external panel with five clinical researchers,
affiliated to the Research on Research group (RoR), Duke
University, to discuss the findings and summarize it as a simulation
model. The simulation was performed by taking the UML activity
diagram as the basis for a System Dynamics model [21,22,23]. All
modeling was conducted using Vensim DSS [40]. This process
involved two steps. First, a baseline model was created to
reproduce the current workflow of each clinical trial site along
with the reported problems related to near miss events for data
quality (Table 2). A system analysis of each major loop in the
system identified points where workflow could be potentially
improved in terms of a better execution of tasks. Second, the
model was presented to each participant for feedback, who
suggested modifications. Interventions were then tested in
subsequent models, where we simulated an improvement in the
system. Finally, the model was fed with qualitative data and
simulated using different scenarios.
Results
Overall, the two sites evaluated in this study demonstrated
consistent data collection system, with only a few discrepancies
between them. The inconsistencies were related to specific
infrastructure aspects. In addition, a group of areas with higher
Table 1. Terminology standardization.
Term Description
Protocol Clinical trial documentation that outlines the objective, methodology, design, analysis plan. It also describes
the background and reason for the conduct of the study and puts forth a standard method for
the conduct of the clinical trial [22]
Actor A person who is a part of the trial workflow and interacts with tasks or other actors [21]
Principal Investigator (PI) An individual who is directly responsible for the conduct and completion of a funded clinical trial.
He/She directs the research project and reports study results directly to the sponsors [22]
Sub-Investigator Physicians designated and supervised by the PI to perform procedures and monitor subjects in the clinical
trial [22]
CRC (Clinical Research Coordinator) Individuals responsible for operational tasks and for providing support to PI/Subinvestigator in a clinical trial
study. They could be involved in the process of inclusion, recruitment and still maintain the registry of
participants, provide the signature of informed consent forms and schedule procedures and lab tests,
ensuring accuracy of source documentation, dispensing study medications and maintaining databases with
clinical research data, filling the CRF [22]
Research Subject Once the patient agrees to be a part of a clinical trial and signed the informed consent document,
he/she becomes a research subject [22]
CRF (Case Report Form) It is a paper-based or electronic record of subject data specifically used in clinical trial research [22]
Source Document a document where collected data is first recorded for a clinical trial and later entered in the CRF [22]
doi:10.1371/journal.pone.0039671.t001
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concept, were also identified, mapped and simulated. In total, we
observed the activities of four Clinical Research Co-ordinators
(CRCs), and identified a total of 139 tasks (Refer to supporting
information S1).
Ethnographic Field Observations and Workflow Mapping
using UML Activity Diagrams
General observations. The UML-AD detected four major
activities in the workflow, namely (a) evaluation of potential
research subjects prior to signature of informed consent (S2), (b)
visit to obtain subjects informed consent (S3), (c) regular data
collection sessions following study protocol (S4), and (d) closure of
study protocol for a given project.
Activity A, prior to the signature of the informed consent, the
potential research subject underwent a clinical exam as well as
additional laboratory exams as per clinical site routine. These are
common pathological exams and work as a pre-screening method.
The results of these exams help in the evaluation of inclusion and
exclusion criteria. During activity B - the visit to obtain subjects
informed consent, potential subjects received an explanation about
the entire study, described in the informed consent form while
being offered the opportunity to ask questions. The PI then
requested the subject to sign the informed consent. At this point an
individual schedule for the study subject was established. Activity
involved a series of encounters representing regular data collection
sessions following the variations across different study protocols.
Finally, during activity D, the subject either reached completion or
was excluded from the study protocol, when study closure was
achieved, including the collection of any remaining interventional
drug when applicable and also included the plan for any further
follow-up when required by protocol. Since each of these activities
is distinct, they were represented by different UML-ADs (Refer
Supporting information S2, S3, S4).
Observations of workflow tasks with higher likelihood of
quality issues. Our field observations pointed to three major
emerging themes (based on table 1) corresponding to areas where
workflow was associated with potential near miss events for data
quality issues.
Lack of standardized process for data registration at
source document. The first emerging theme resulted from the
presence of a number of intermediate documents in the transfer of
data from research subject to the electronic CRF by CRC.
Examples include: (a) Nurse reports were paper-based and later
manually transferred to an electronic data capture system; b) Drug
stock control was made on tables of text editor or spreadsheet and
then printed; c) Results from laboratory exams were printed from
their home pages or received by email and subsequently printed,
or printed from laboratory computer system applications.
Although all of these sources do not violate any current Good
Clinical Practice regulations, as CRFs were filled out based on the
original source data, the presence of intermediate documents –
even if used only for care purposes - increases the odds of error
secondary to unintentional transcription errors. In addition, these
intermediate steps represent rework.
Multiplicity of data repositories. We observed that the
information being transferred was registered in different binary
files such as Microsoft Word and Excel files. The files were not
linked and later were manually transferred using a copy and paste
functionality. In one of the sites, documents directly filled out with
subjects information were not directly inserted into the CRF by
the CRC, but remained in paper-format (source document) for
later transcription into the electronic CRF.
The paper-based documentation trail also results in search-
ability problems, in that, locating specific data fields for validating
systems in the area or when checking for possible errors was time-
consuming. Adding to the complexity of this process, research
nurses were required to fill out multiple forms in accordance to
study protocol, this information being transcribed by investigators
and later copied and finally pasted by the CRCs. Other parallel
systems also contained different, non inter-operable systems such
as pharmacy services using multiple Microsoft Excel and Word
documents for stock control, drug validity, and medication
disposal.
Scarcity of decision support systems at the point of
research intervention. Given that a single CRC is concom-
itantly in charge of multiple studies, it is not unusual that the
information about specific details pertaining to each study were
sometimes forgotten. This oversight resulted in a major rework
loop, in that the correction could only be accomplished through
the central coordinating center located in the European Union,
not before having to contact the central coordinator for Brazil.
The total rework process resulted in a total time loss of
approximately two uninterrupted hours. In another instance, the
complete period to complete a CRF lasted about one hour,
reportedly at least three times more than what that task would
Table 2. Variables classified as problematic on visited sites.
Visit-EDC asynchrony The CRC does not have the time to transcribe the content from the paper-based or
electronic medical record to the computerized electronic data capture (EDC) in a
timely manner.
EMR-EDC non-interoperability Electronic medical record (EMR) not integrated with EDC, therefore may cause error or
lack of information during transcription from one the EMR computer screen
to the one for the EDC.
CRC-data entry discontinuity At the time of the encounter with the subject, investigator takes notes on the EMR,
nurse takes note on nurse plan and CRC makes the final data entry into EDC.
Lab-EDC non-interoperability Laboratory system not integrated with EMR, requiring re-entry with potential for
transcription errors.
Decentralized accounting for drug dispensation System for drug stock control between pharmacy and trials use different systems,
with a potential for discrepancy and error.
Lack of decision support systems to assist CRC CRC frequently has to consult a variety of documents not available at the time of
interaction with research subject. This factor is compounded by a single CRC being
in charge of multiple studies supported with paper-based documentation, which
might lead to confusion and error.
doi:10.1371/journal.pone.0039671.t002
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although she had undergone previous training, that training had
occurred several months before and most study-related processes
were new, requiring constantly re-checking to ensure information
accuracy. Since the documentation was long and not easy to
search, the whole workflow was significantly delayed, ultimately
affecting the CRC’s ability to complete it on time. With this delay,
some of the CRF completion was left to another person on staff,
enhancing the probability of near miss events for data quality
issues. Other unexpected tasks for which there is no automation
also prevented that the CRC complete the protocol on time, such
as accounting issues related to the appointment such as the CRC
spending one complete morning solving financial problems related
to the study. In addition, study manuals frequently were confusing
and lacked appropriate usability as attested by confusion generated
while the CRC attempted to interpret them.
Preliminary Simulation Model
The preliminary simulation model (Figure 1) envisioned the
following three main emerging themes (S5) generating rework: 1)
Lack of standardized process for data registration at source
document, 2) Multiplicity of data repositories and 3) Scarcity of
decision support systems at the point of research intervention. The
model has the following features: (a) all emergent themes are
represented as stocks (rectangle), (b) a blue arrow represents
information input and (c) a red arrow represents some action that
will limit the growth of a stock.
The theme ‘‘lack of standardized processes’’ has as its central
feature represented by a stock ‘‘CRF information accuracy’’.
Aligned with our ethnographic findings, the variable representing
‘‘intermediate forms of documentation’’ has a negative influence
over ‘‘accuracy of information’’. The variable ‘‘accuracy of
information’’ will speed up the processing of CRF completion.
In other words, the greater the ‘‘accuracy information’’, less delay
in successfully completing CRFs we will have.
The second theme ‘‘multiplicity of data repositories’’ is
represented by a stock of reliable CRF information. Aligned with
our ethnographic observations, it was seen in the form of three
types of data repositories of information that would lead to the
same information in different formats (Word documents, spread-
sheets in Excel and software applications like central pharmacy or
laboratories). In our model, we simulated how data multiplicity
would affect reliability of CRF information. In our model the
variable ‘‘data repository multiplicity’’ is influenced by three
distinct variables: ‘‘other applications’’ (laboratories application,
central pharmacy application and others), ‘‘text editor files’’ (Word
documents), and ‘‘spreadsheet files’’ (Excel documents). The
variable ‘‘data repository multiplicity’’ has a negative effect on
the variable ‘‘information reliability.’’ In other words, the greater
the multiplicity of data sources, the less reliable the information
and the greater the delay in successful completion of CRFs.
The third theme ‘‘scarcity of decision support system at the
point of research intervention’’ indicates that the current work-
flows for filling out paper and computer-based CRFs are in need of
a better decision support system. The model also contains a
variable representing the ‘‘efficiency of a support system,’’ which
positively impacts the speed in completing CRFs.
Additionally, we can observe that the main variables of our
model ‘‘intermediate forms of documentation’’, ‘‘data repository
multiplicity’’ and ‘‘support of information’’ are influencing another
variable called ‘‘Error Fraction’’. The variable ‘‘Error Fraction’’ is
used in our model to represent the stocks – ‘CRF to Do’, ‘Rework’
and ‘CRF Completed’. It receives information from the left part of
model, representing the three emergent themes and has a directly
proportional relationship with the variable - ‘‘Rework’’ flow. This
means that higher instances of ‘Error’ will generate more rework
and as a result lesser CRFs will be completed.
As we did not have access to real data, we made the following
assumptions: the values for ‘‘intermediate of documents’’ and
‘‘multiplicity of data repositories’’ was simulated starting on zero
and growing each six months until the limit of 20% and 30%
Figure 1. System dynamics model showing the three major emerging themes identified and rework caused by these themes.
Available for best visualization in http://goo.gl/XydTd.
doi:10.1371/journal.pone.0039671.g001
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simulate a situation where the staff started working with no
problems but faced them increasingly over time. The value of
efficiency of support system were simulated with 50% all the time,
with this parameter we simulate a system with 50 percent
deficiency.
We present two situations based on the outcomes of simulating
the model (figure 2). In the first situation labeled as ‘‘planned’’, we
assume the lack of an error in the work done. The simulation
results represent CRFs to be done and CRFs completed. In the
second situation labeled as ‘‘Simulated with Rework’’ we
attempted to simulate of what happened on observed environ-
ment. This simulation was based on three emergent themes
presented in this manuscript. In this second situation work could
not be completed as planned. This was primarily a consequence of
rework that was generated because of error fraction caused by
emergent themes consequences (rework point on figure 2).
Policy Model Results
The policy model results were divided into three categories of
policies with an aim to reduce the rework: (a) Standardized process
procedure, (b) Integration of application systems, (c) Improvement
of support systems (figure 3). In ‘‘standardized process procedure’’
policy, we suggest the clinical trial administrative staff of each site
to periodically revise their standard procedures and perform
training with the research team when working with CRFs to
decrease the creation of intermediate documents. For the policy
‘‘integration of application systems’’ the clinical trial administra-
tive staff must work together with IT staff of a site and analyse all
the data repositories created in duplicity (as observed during our
ethnographic study) and create a solution where the clinical trial
staff will insert information in only one application to avoid these
duplicities. Finally, in the ‘‘improvement of support systems’’
policy, the clinical trial administrative staff and sponsors need to
work more efficiently to obtain support information more fast and
friendly when working with CRF. For each one of these policies
the PI, CRC’s, nurses, pharmacists and receptionist involved in
clinical trial procedures must be trained in new methods and
procedures that can facilitate the use of information and resources
more efficiently while reducing rework.
As a result of policies applied (figure 4), we observe the latter
leads to more CRF’s completed, resulting in less rework.
Rework does not disappear altogether but reduces. In course of
time, if policies are well implemented, rework should tend
towards zero.
Figure 5 gives us an idea of workflow behaviour in our
simulation. The dotted line represents workflow planned, which
should be complete a thousand of CRFs for ten months. The
straight line represents the simulation performed with rework
caused by three emerging themes identified. In this situation, the
workflow has been increased in order to be able to complete a
thousand CRFs which will need twelve months. The dotted line
Figure 2. CRF’s to do and CRF’s completed in two situations: planned and simulated with rework.
doi:10.1371/journal.pone.0039671.g002
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time to complete CRF was reduced. The ideal workflow may
depend on factors that of not immediate implementation,
therefore the implementation of the policies had a small reduction
of rework and still kept it.
Discussion
To the best of our knowledge, this is the first study evaluating
and mapping workflow at clinical trial sites while also conducting a
simulation to represent the potential for improvement once the
main issues were addressed.
In our study, several factors affecting workflow pointed towards
the lack of interoperability between the electronic medical record
and electronic data capture system at the clinical trial site, namely
visit-EDC asynchrony, EMR-EDC non-interoperability, lab-EDC
non-interoperability, decentralized accounting for drug dispensa-
tion). Factors affecting this relation included the presence of
standalone and disconnected systems taking care of schedule
management, administration, lab reporting, medical records, and
research databases. This results in fragmented and siloed data that
are seldom useful for research purposes. In many cases, it has been
noted that the data from EMR cannot be directly utilized in a
clinical trial environment on account of incompatible data formats
and non adherence to clinical research regulations [41]. As a
consequence, despite the availability of state of art systems,
information is frequently recorded manually on charts followed by
separate data entry into the EMR and EDC. The lack of
interoperability thus leads to less efficiency, duplication [41], and
errors, leading to disruption of the clinical trial pipeline and
damages estimated in million dollars/year.
In our study, near miss events for data quality were also
influenced by a discontinuity in performance of a specific task.
Specifically, rather than having one individual performing the
entire task, the process was broken and implemented by more than
one individual. Although this practice is aimed at workflow
distribution and enhancing productivity and efficiency of different
individuals it also serves to increase the possible flow quality
Figure 3. Dynamic model with the policies suggested (circled). Available for best visualization in http://goo.gl/XydTd.
doi:10.1371/journal.pone.0039671.g003
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information about the subject handling the data. Previous
literature suggests that interruption during task implementation
may not only have a negative effect on task performance but also
lead to serious errors [42]. For example, CRCs may receive
unexpected workload and thus forget a critical portion of their task
lists or incur in data entry errors [13].
We also noted that an absence of decision support systems for
clinical research coordinators had a significant influence on their
task performance and resultant near miss events for data quality.
Clinical research coordinators and physicians frequently need to
answer queries or consult the study material while evaluating a
research subject. Lack of readily available guidelines has
implications on time and effective subject management in a
clinical trial. In our study we identified difficulties encountered by
CRC to quickly locate information while handling long paper-
based protocols. This difficulty could be alleviated with, for
example, electronic documents with better navigability that could
be immediately queried at the time when they are needed.
Although the benefits of decision support systems in enhancing the
safety and quality of clinical practice [43,44,45], reducing errors
[46,47] and ensuring adherence to practice guidelines [48,49] has
amply been demonstrated in the past, they are equally useful in
clinical research settings. In the latter context, decision support
tools have been effectively used to determine subject eligibility
[50,51]. Based on our results, the implementation of a decision
support tool to guide CRC tasks would similarly result in the
optimization of clinical trial tasks.
Although our report has made a significant contribution in
terms of understanding, representing, and simulating strategic
workflow decisions to reduce the incidence of near miss data
quality issues in clinical trial sites, our study has limitations. As in
any observational study, the presence of observers in the clinical
trial site might interfere with the way subjects behave, potentially
introducing bias into our observations [52]. However, since most
of our findings were confirmed by triangulation [53] to be part of
the daily routine of the investigated sites, this effect should be
considered minimal.
The results obtained from the suggested interventions imple-
mented in our model simulation were not validated through real
life implementation, since it would require a substantial investment
from the site and sponsor’s perspective. Given the highly regulated
environment within clinical trials, the level of variability in our
UML model is reduced thus enhancing its applicability. Several of
the investigators were familiar with the clinical trial process and,
therefore, could have unintentionally introduced their opinions
into the observational process.
Another issue in comparing workflows across trial sites is the
absence of a taxonomy listing variables that should be compared.
This taxonomy would ideally focus on areas of dissonance between
workflow and data quality and requires a specific article describing
this approach. Moreover, although the two sites where we
collected data represent active Cancer trial sites in Brazil, our
sample size was small and may not be judged representative. A
larger sample size could increase the generalizability of our results,
but qualitative studies are aimed at depth rather than generaliz-
Figure 4. CRF’s to do and CRF’s completed in two situations: simulated with rework and simulated with policies suggested.
doi:10.1371/journal.pone.0039671.g004
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site.
Although we conducted our study in a developing country
(Brasil), there is little evidence to suggest that the problems we
describe are restricted to developing countries. Moreover, the low
granularity of our system level recommendations is justified given
its occurrence every time a new approach is applied to a field.
Given that, to the best of our knowledge, this is the first study
evaluating and mapping workflow at clinical trial sites while also
simulating its results using System Dynamics.
Finally, we make a substantial assumption that near-miss events
are a proxy for real data quality events. This assumption was made
given the qualitative nature of our study, where samples are
frequently small and exploratory, therefore unable to reach results
that would qualify as definitive. However, we would also like to
point that an assumption of association between near miss and
‘‘real events’’ has been made in a wide range of the literature and
ratified by entities such as the Institute of Medicine in its report
‘‘To err is human’’ [54].
In conclusion, in order to reduce rework and optimize trial
performance, it is essential to improve the efficiency prevailing in
trial sites. Clinical trial sites and sponsors should review and
improve their standard procedures and manage human resource
allocation to better address the workflow issues summarized in our
study. Sponsors and site managers can improve support systems
for CRCs. Although some interventions such as integration
between EMR and EDC, might not seem cost-effective or even
technologically possible at this time, strategic decisions should be
made to facilitate their future integration. For example, when
planning for an EMR system, hospital administrators should
evaluate the ease of integration with external EDCs. Also, future
research should integrate systems modeling simulation so that
these changes can be constantly monitored and frequently
evaluated in the quest for data quality excellence. As a future
study we intend to submit a new manuscript about the new
taxonomy for what should be compared in workflows across sites
focusing on areas of dissonance between workflow and data
quality.
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